Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

To be considered for this study, you must be an adult aged 18 or older. You would need to have certain kidney conditions such as IgA nephropathy (IgAN), C3 glomerulopathy (C3G), or IC-MPGN, and this diagnosis must have been confirmed by a kidney biopsy. Your kidney function, measured by something called eGFR, should be at a certain level, and you should be receiving standard care for your kidney disease, which might include specific blood pressure medicines if your doctor thinks they are appropriate.

There are also reasons why you might not be able to join. For example, if you've had a kidney transplant or other organ transplants, or if you're currently on dialysis. You also couldn't take part if you have certain problems with your immune system, another type of kidney disease, or a history of frequent severe infections. If you've recently had other treatments that affect the complement system, or if you have severe liver problems, you'd also not be able to join.

If you decide to take part in this study, you would receive the study medicine, ADX-038, at one of two dose levels chosen by the study team. You would have regular visits to the clinic for health checks, blood tests, and other assessments to monitor your kidney function and how you're responding to the medicine. You would also need to be willing to get certain vaccinations to ensure your safety during the study. The total duration of your participation, including follow-up, will be explained in detail by the study team.